AR016312A1 - USO DE UN COMPUESTO DE MEJORAMIENTO DE LA ADINISTRACIoN DE AGENTES TERAPÉUTICOS, COMPOSICIONES FARMACÉUTICAS Y DICHO COMPUESTO. - Google Patents

USO DE UN COMPUESTO DE MEJORAMIENTO DE LA ADINISTRACIoN DE AGENTES TERAPÉUTICOS, COMPOSICIONES FARMACÉUTICAS Y DICHO COMPUESTO.

Info

Publication number
AR016312A1
AR016312A1 ARP980103311A ARP980103311A AR016312A1 AR 016312 A1 AR016312 A1 AR 016312A1 AR P980103311 A ARP980103311 A AR P980103311A AR P980103311 A ARP980103311 A AR P980103311A AR 016312 A1 AR016312 A1 AR 016312A1
Authority
AR
Argentina
Prior art keywords
compound
administration
pharmaceutical compositions
therapeutic agents
improvement
Prior art date
Application number
ARP980103311A
Other languages
English (en)
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of AR016312A1 publication Critical patent/AR016312A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composiciones y métodos para mejorar la entrega de agentes moduladores a las células para fines terapéuticos. Los agentes moduladores, que incluyencompuestos terapéuticos, pueden incluir polipéptidos, polinucleotidos tales como genes, ácidos nucléicos antisentido, una matriz polimérica y otras moléculas yvectores virales que pueden modular la actividad celular o funciones cuando son introducidas dentro de las células. Los agentes mejoradores aumentan lahabilidad del agente modulador para entrara la célula. La administracion del agente mejorador puede ser formulado en un bufer farmacéuticamente aceptable paralas distintas administraciones farmacéuticas.
ARP980103311A 1997-07-08 1998-07-08 USO DE UN COMPUESTO DE MEJORAMIENTO DE LA ADINISTRACIoN DE AGENTES TERAPÉUTICOS, COMPOSICIONES FARMACÉUTICAS Y DICHO COMPUESTO. AR016312A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/889,355 US7002027B1 (en) 1996-01-08 1997-07-08 Compositions and methods for therapeutic use

Publications (1)

Publication Number Publication Date
AR016312A1 true AR016312A1 (es) 2001-07-04

Family

ID=25394956

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103311A AR016312A1 (es) 1997-07-08 1998-07-08 USO DE UN COMPUESTO DE MEJORAMIENTO DE LA ADINISTRACIoN DE AGENTES TERAPÉUTICOS, COMPOSICIONES FARMACÉUTICAS Y DICHO COMPUESTO.

Country Status (21)

Country Link
US (3) US7002027B1 (es)
EP (2) EP1011733B1 (es)
JP (2) JP4460148B2 (es)
KR (1) KR100691572B1 (es)
AR (1) AR016312A1 (es)
AT (2) ATE434448T1 (es)
AU (1) AU774338B2 (es)
CA (1) CA2294709C (es)
CY (1) CY1109367T1 (es)
DE (2) DE69840932D1 (es)
DK (1) DK1011733T3 (es)
ES (2) ES2362027T3 (es)
HK (2) HK1028961A1 (es)
HU (1) HUP0002683A3 (es)
IL (1) IL133929A0 (es)
MY (1) MY138257A (es)
NZ (1) NZ502060A (es)
PT (1) PT1011733E (es)
TW (1) TW490306B (es)
WO (1) WO1999002191A1 (es)
ZA (1) ZA986003B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
EP1070047A2 (en) 1998-04-08 2001-01-24 Celltech Chiroscience Limited Lipids
AU2002366809A1 (en) * 2001-12-20 2003-07-09 Schering-Plough Corporation Syn3 compositions and methods
CN100429220C (zh) * 2003-06-04 2008-10-29 坎基股份有限公司 用于干扰素治疗的方法和组合物
CA2527658A1 (en) * 2003-06-04 2004-12-16 Canji, Inc. Methods and compositions for interferon therapy
US7790039B2 (en) * 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
WO2005058368A1 (en) * 2003-12-10 2005-06-30 Canji, Inc. Methods and compositions for treatment of interferon-resistant tumors
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
WO2007030588A1 (en) * 2005-09-07 2007-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
WO2009136396A2 (en) * 2008-05-05 2009-11-12 Tiltan Pharma Ltd. Sulfobetaines for therapy
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
EP4089169A1 (en) 2009-10-12 2022-11-16 Larry J. Smith Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
US20120147800A1 (en) * 2010-12-10 2012-06-14 Minyoung Park Power management in a wireless network having stations with different power capabilities
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
US10492104B2 (en) * 2016-03-10 2019-11-26 Cable Television Laboratories, Inc. Latency reduction in wireless service

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554386A (en) 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6207454B1 (en) 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5120316A (en) 1990-09-28 1992-06-09 Akzo N.V. Urethral catheter and catheterization process
JPH07500961A (ja) 1990-10-01 1995-02-02 ユニバーシティ オブ コネチカット 細胞による選択的内在化を目的としたウイルス及び細胞の標的設定
DE59108326D1 (de) * 1990-12-06 1996-12-12 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindung als Arzneimittel
JPH06509329A (ja) 1991-06-28 1994-10-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 細胞の部位特異的な点滴注入または細胞の部位特異的形質転換による疾患の治療およびそのためのキット
WO1993002556A1 (en) 1991-07-26 1993-02-18 University Of Rochester Cancer therapy utilizing malignant cells
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5602023A (en) 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
ATE260679T1 (de) 1992-04-03 2004-03-15 Univ California Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
CA2133411A1 (en) 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5656609A (en) 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
WO1994006923A1 (en) 1992-09-24 1994-03-31 The University Of Connecticut Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
JPH07109983A (ja) 1993-10-13 1995-04-25 Nippondenso Co Ltd スクロール型圧縮機
AU8076494A (en) 1993-10-15 1995-05-04 Cytrx Corporation Therapeutic delivery compositions and methods of use thereof
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5552309A (en) 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
WO1997005209A1 (en) * 1995-07-28 1997-02-13 Kohne David E Method for enhancing chemiluminescence
US20040014709A1 (en) 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US5671110A (en) 1996-01-23 1997-09-23 Oneac Corporation Ground skew protection method and apparatus
US6283940B1 (en) * 1997-08-29 2001-09-04 S. Grant Mulholland Catheter
US6938069B1 (en) * 2000-03-18 2005-08-30 Computing Services Support Solutions Electronic meeting center
AU2002366809A1 (en) 2001-12-20 2003-07-09 Schering-Plough Corporation Syn3 compositions and methods
KR100499787B1 (ko) 2002-11-29 2005-07-07 인티그런트 테크놀로지즈(주) 스위치 모드 동작을 하는 선형성이 우수한 광대역 가변이득 증폭기
CN100429220C (zh) 2003-06-04 2008-10-29 坎基股份有限公司 用于干扰素治疗的方法和组合物
CA2527658A1 (en) 2003-06-04 2004-12-16 Canji, Inc. Methods and compositions for interferon therapy
WO2004108898A2 (en) 2003-06-04 2004-12-16 Canji, Inc. Transfection agents
WO2005058368A1 (en) 2003-12-10 2005-06-30 Canji, Inc. Methods and compositions for treatment of interferon-resistant tumors

Also Published As

Publication number Publication date
HK1134025A1 (en) 2010-04-16
US8022044B2 (en) 2011-09-20
EP1011733A4 (en) 2004-09-29
JP4460148B2 (ja) 2010-05-12
EP2106807B1 (en) 2011-02-09
US20060199782A1 (en) 2006-09-07
HUP0002683A2 (hu) 2000-12-28
DE69842133D1 (de) 2011-03-24
JP2010070565A (ja) 2010-04-02
US7538093B2 (en) 2009-05-26
HK1028961A1 (en) 2001-03-16
AU8390198A (en) 1999-02-08
CA2294709A1 (en) 1999-01-21
DE69840932D1 (de) 2009-08-06
NZ502060A (en) 2003-01-31
KR100691572B1 (ko) 2007-03-12
EP1011733B1 (en) 2009-06-24
US7002027B1 (en) 2006-02-21
KR20010021620A (ko) 2001-03-15
ES2362027T3 (es) 2011-06-27
CA2294709C (en) 2010-05-11
AU774338B2 (en) 2004-06-24
DK1011733T3 (da) 2009-09-28
ATE434448T1 (de) 2009-07-15
CY1109367T1 (el) 2014-07-02
ES2328094T3 (es) 2009-11-06
JP2001509492A (ja) 2001-07-24
MY138257A (en) 2009-05-29
PT1011733E (pt) 2009-09-15
EP1011733A1 (en) 2000-06-28
HUP0002683A3 (en) 2005-09-28
US20100028431A1 (en) 2010-02-04
WO1999002191A1 (en) 1999-01-21
TW490306B (en) 2002-06-11
ATE497786T1 (de) 2011-02-15
ZA986003B (en) 1999-01-28
EP2106807A1 (en) 2009-10-07
IL133929A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
AR016312A1 (es) USO DE UN COMPUESTO DE MEJORAMIENTO DE LA ADINISTRACIoN DE AGENTES TERAPÉUTICOS, COMPOSICIONES FARMACÉUTICAS Y DICHO COMPUESTO.
DK0559884T4 (da) Rekombinante virusvektorer til ekspression i muskelceller
GB9506466D0 (en) Cell cycle regulated repressor and dna element
GR3035050T3 (en) Method of preparing a viral vector by homologous intermolecular recombination
NO962791L (no) Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse
ES2010226A6 (es) Un procedimiento para producir una preparacion farmaceutica estable que contiene un factor estimulante de colonias de granulocitos
BR9813202B1 (pt) complexo de administração de genes; processo de transdução de células com material genético estranho, composição útil para administração de material genético e uso de um complexo de administração de genes.
ES2150894T1 (es) Vector de baculovirus modificado por proteinas de envoltura para terapia genica.
IT8921243A0 (it) Nuovi geni ibridi funzionali di bacillus thuringiensis ottenuti mediante ricombinazione in vivo.
AR019699A1 (es) Composicion farmaceutica para el tratamiento de disfuncion de la evacuacion y uso de la misma para la preparacion de un agente terapeutico
IL121272A0 (en) Nucleotide comprising compositions and their use for improving therapeutic index of a therapeutic drug
AR017368A1 (es) Un procedimiento para la insercion de adn foraneo en una celula hospedante, un vector recombinante utilizado en dicho procedimiento y el uso del mismo
DK0843731T3 (da) Adenovirusvektorer til genterapi
DK1007717T3 (da) Metoder og sammensætninger til cancerterapi under anvendelse af gener, der koder for interferon-beta
AU6587998A (en) Ligand/lytic peptide compositions and methods of use
FR2732978B1 (fr) Vecteur viral recombinant, composition pharmaceutique le contenant et cellules transformees correspondantes
NO992577D0 (no) Transfeksjonsblanding for anvendelse ved genterapi og som kombinerer en rekombinant virus som inkorporerer en exogen nukleinsyre, med et ikke-viralt, ikke-plasmidisk transfeksjonsmiddel
ATE311886T1 (de) Verwendung einer zusammensetzung enthaltend 5- androsten-3beta,17alpha-diol
WO1998058955A3 (en) Nuclear matrix targeting peptides and uses therefor
EP1878438A3 (en) Ligand/llytic peptide compositions and methods of use
AU7370798A (en) Compositions and methods of therapy for igf-i-responsive conditions
AR004227A1 (es) Uso de hialuronan en terapia genetica.
MX9708111A (es) Lipidos cationicos para terapia genica.

Legal Events

Date Code Title Description
FB Suspension of granting procedure